Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Fujifilm Diosynth Biotechnologies has opened its new manufacturing plant in Billingham, UK. It was partly built for one of its unnamed customers that is developing a therapy for wet age-related macular degeneration. The new facility also has microbial fermentation production capabilities, according to a Tuesday release.
Bora Pharmaceuticals has completed its $30 million acquisition of a 87,000 square foot drug production facility in Baltimore-Camden, MD, from Emergent BioSolutions, according to a Tuesday press release.
CDMO Touchlight is helping the University of Nottingham to scale up production and development of a new Zika virus vaccine. Touchlight will produce DNA on a large scale, the university said Wednesday.
CDMO ST Pharm has partnered with RNA tech company Quantoom Biosciences to develop and manufacture RNA-based vaccines and other therapies. ST Pharm will provide its manufacturing services, and Quantoom will give access to its technology platforms, a Tuesday release states.
CDMO VGXI has been accepted into the Biopharmaceutical Manufacturing Preparedness (BioMap) Consortium, which is focused on expanding the US’ manufacturing footprint, as per a Tuesday release. The consortium is supported by the Biomedical Advanced Research and Development Authority (BARDA).
Uranium and vanadium producer Energy Fuels has acquired radioisotope producer RadTran. The buy will help Energy Fuels produce medical radioisotopes, the company said on Monday.
CDMO Scorpius Holdings’ revenue for the second quarter of 2024 increased by 16% to $760 million compared to the $658 million reported in the same period last year, the company said Tuesday. The CDMO currently has $1.5 billion in cash and cash equivalents.
Eugia Pharma Specialities has received an FDA warning letter after an inspection at its facility in Hyderabad, India, between Jan. 22 and Feb. 2. The letter said the facility had data records that were inaccurate, records for cleaning weren’t kept properly and the company didn’t investigate any batch discrepancies.
Tonix Pharmaceuticals touted that its manufacturing site in Dartmouth, MA, has ready-to-use capacity to make its horsepox vaccine in case of a national or international emergency, the company said in its second-quarter earnings report Monday.